This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Compounds of the general formula (I):



in which:

X = O or S;

R1 is chosen from:

- Alk-COOH,
- Alk-C(=O)-$(O)_m$-Ar,
- Alk-C(=O)-$(O)_m$-Het,
- Alk-C(=O)-$(O)_m$-Alk,
- Alk-C(=O)-$(O)_m$-cycloalkyl,
- Alk-C(=O)NRR',
- Alk-$(O)_m$-Ar,
- Alk-O-Alk,
- Alk-O-Alk-Ar,
- Alk-O-Het,

R2 is chosen from -Alk, -Ar and -cycloalkyl;

R3, R4, R5 and R6, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, $-CF_3$, -NRR' and $-NO_2$;

in which, in the definitions of R1-R6:

each of the Alk, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -COOH, -NRR', -C(=O)-$(O)_m$Alk, -Het and $-NO_2$;

each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -AlkAr, -COOH, $-C(=O)-(O)_mAlk$, $-Alk-C(=O)-(O)_m-Alk$, -NRR', -Het, $-NO_2$, $-S(O)_nAr$ and $-S(O)_nAlk$;

R and R' are chosen independently from H and Alk;

m = 0 or 1;

and also the stereoisomers thereof, the racemates thereof and the pharmaceutically acceptable salts,

with the exception of the compounds for which:

1) R1 = $-CH_2-C(=O)Me$, R2 = -Me, X = O, R3, R5 = H and each R4, R6 = H or OMe.

2. (Original) Compounds of the formula (I) according to Claim 1, in which:

X = O or S;

R1 is chosen from:

- Alk-COOH,
- $Alk-C(=O)-(O)_m-Ar$,
- $Alk-C(=O)-(O)_m-Het$,
- $Alk-C(=O)-(O)_m-Alk$,
- $Alk-C(=O)-(O)_m-cycloalkyl$,
- Alk-C(=O)NRR',
- $Alk-(O)_m-Ar$,
- Alk-O-Alk,
- Alk-O-Alk-Ar,
- Alk-O-Het,

R2 represents -Ar or -cycloalkyl;

R3, R4, R5 and R6, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, $-CF_3$, -NRR' and $-NO_2$;

in which, in the definitions of R1-R6:

each of the Alk, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr,

$-CF_3$, -COOH, -NRR', $-C(=O)-(O)_mAlk$, -Het and $-NO_2$;

each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -AlkAr, -COOH, $-C(=O)-(O)_mAlk$, $-Alk-C(=O)-(O)_m-Alk$, -NRR', -Het, $-NO_2$, $-S(O)_nAr$ and $-S(O)_nAlk$;

R and R' are chosen independently from H and Alk;

m = 0 or 1,

and also the stereoisomers thereof, the racemates thereof and the pharmaceutically acceptable salts.

3. (Original) Compounds of the formula (I) according to Claim 1, in which:

X = S;

R1 is chosen from:

- Alk-COOH,
- $Alk-C(=O)-(O)_m-Ar$,
- $Alk-C(=O)-(O)_m-Het$,
- $Alk-C(=O)-(O)_m-Alk$,
- $Alk-C(=O)-(O)_m-cycloalkyl$,
- Alk-C(=O)NRR',
- $Alk-(O)_m-Ar$,
- Alk-O-Alk,
- Alk-O-Alk-Ar,
- Alk-O-Het,

R2 is chosen from -Alk, -Ar and -cycloalkyl;

R3, R4, R5 and R6, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, $-CF_3$, -NRR' and $-NO_2$;

in which, in the definitions of R1-R6:

each of the Alk, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -COOH, -NRR', $-C(=O)-(O)_mAlk$, -Het and $-NO_2$;

each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -AlkAr, -COOH, $-C(=O)-(O)_mAlk$, $-Alk-C(=O)-(O)_m-Alk$, -NRR', -Het, $-NO_2$, $-S(O)_nAr$ and $-S(O)_nAlk$;

R and R' are chosen independently from H and Alk;

m = 0 or 1;

and also the stereoisomers thereof, the racemates thereof and the pharmaceutically acceptable salts.

4. (Currently Amended) Compounds of the formula (I) according to claim 1 ~~any one of the preceding claims~~, in which R3, R4, R5, R6 = H.

5. (Currently Amended) Compounds of the formula (I) according to claim 1 ~~any one of the preceding claims~~, in which X = S.

6. (Currently Amended) Compounds of the formula (I) according to claim 1 ~~any one of the preceding claims~~, in which R2 = Ar optionally substituted by -CN or -COOH, or alkyl optionally substituted by -COOH.

7. (Currently Amended) Compounds of the formula (I) according to claim 1 ~~any one of the preceding claims~~, in which R2 = phenyl optionally substituted by -CN or -COOH.

8. (Currently Amended) Compounds of the formula (I) according to claim 1 ~~any one of the preceding claims~~, in which R2 = phenyl substituted by -CN.

9. (Currently Amended) Compounds of the formula (I) according to claim 1 ~~any one of the preceding claims~~, in which m = 0.

10. (Currently Amended) Compounds of the formula (I) according to claim 1 ~~any one of the preceding claims,~~ in which R1 = $-CH_2-COOH$, $-CH_2-C(=O)-(O)_m-Ar$, $-CH_2-C(=O)-(O)_m-Het$, $-CH_2-C(=O)-(O)_m-Alk$, $-CH_2-C(=O)NRR'$, $-CH_2-(O)_m-Ar$, $-CH_2-O-Alk$, $-CH_2-O-Alk-Ar$ or -

CH_2-O-Het, in which

Ar is optionally substituted by one or more groups chosen from Hal, -OAlk, -Ar, -Alk, -O-Alk-Ar, -C(=O)-$(O)_m$-Alk, -Alk-C(=O)-$(O)_m$Alk, -$S(O)_n$-Ar, -$S(O)_n$-Alk, -O-CF_3, -CN and -OH, in which m = 0 or 1, n = 2.

11. (Currently Amended) Compounds of the formula (I) according to claim 1 ~~any one of the preceding claims~~, in which R1 = -CH_2-C(=O)-Ar, -CH_2-C(=O)-Alk or -$(CH_2)_m$'-$(O)_m$-Ar, in which Ar is optionally substituted by one or more groups chosen from Hal, -OAlk, -Ar, -Alk, O-Alk-Ar, -C(=O)-$(O)_m$-Alk, -Alk-C(=O)-$(O)_m$Alk, -$S(O)_n$-Ar, -$S(O)_n$-Alk, -O-CF_3, -CN and -OH,

in which m = 0 or 1, m' = 1 or 2, n = 2.

12. (Currently Amended) Compounds of the formula (I) according to claim 1 ~~any one of the preceding claims~~, in which m' = 2 if m = 1.

13. (Currently Amended) Compounds of the formula (I) according to claim 1 ~~any one of the preceding claims~~, in which R1 = -CH_2-C(=O)-Alk.

14. (Original) Compounds of the formula (I) according to Claim 13, in which Alk = -CMe_3.

15. (Currently Amended) Compounds of the formula (I) according to claim 1 ~~any one of the preceding claims~~, in which Ar = phenyl.

16. (Currently Amended) Compounds of the formula (I) according to claim 1 ~~any one of the preceding claims~~, in which R1 = -CH_2-C(=O)-phenyl or -CH_2-phenyl in which phenyl is optionally substituted by one or more groups chosen from -Hal, -OAlk, -CN, -SO_2-Alk and -Alk.

17. (Currently Amended) Compounds of the formula (I) according to claim 1 ~~any one of the preceding claims~~, chosen from:

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-chlorophenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-phenylethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2-methoxyphenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-biphenyl-4-ylethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-*p*-tolylethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-methoxyphenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-fluorophenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(3-methoxyphenyl)ethanone;

methyl 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-3-methoxypropionate;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2-benzyloxyphenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-benzyloxyphenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(3,4-dimethoxyphenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-phenylpropan-1-one;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2,4-dimethoxyphenyl)ethanone;

1-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-3,3-dimethylbutan-2-one;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-naphthalen-2-ylethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2,3-dichloro-4-methoxyphenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(4-benzyloxy-3-methoxyphenyl)ethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-1-(2-benzyloxy-5-fluorophenyl)ethanone;

(3-hydroxybenzo[*b*]thiophen-2-yl)phenylmethanone;

2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)acetamide;

{3-[2-(4-fluorophenoxy)ethoxy]benzo[*b*]thiophen-2-yl}phenylmethanone;

(3-phenethyloxybenzo[*b*]thiophen-2-yl)phenylmethanone;

methyl 3-{4-[2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)ethoxy]phenyl}propionate;

{3-[2-(naphthalen-1-yloxy)ethoxy]benzo[*b*]thiophen-2-yl}phenylmethanone;

{3-[2-(2-methoxyphenoxy)ethoxy]benzo[*b*]thiophen-2-yl}phenylmethanone;

1-{4-[2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)ethyl]phenyl}ethanone;

ethyl 2-(2-benzoylbenzo[*b*]thiophen-3-yloxy)-4-phenylbutyrate;

[3-(3-phenoxypropoxy)benzo[*b*]thiophen-2-yl]phenylmethanone;

[3-(4-*tert*-butylbenzyloxy)benzo[*b*]thiophen-2-yl]phenylmethanone;

[3-(2-benzenesulfonylmethylbenzyloxy)benzo[*b*]thiophen-2-yl]phenylmethanone;

methyl 4-(2-benzoylbenzo[*b*]thiophen-3-yloxymethyl)benzoate;

phenyl[3-(4-trifluoromethoxybenzyloxy)benzo[*b*]thiophen-2-yl]methanone;

[3-(biphenyl-2-ylmethoxy)benzo[*b*]thiophen-2-yl]phenylmethanone;

[3-(4-methylbenzyloxy)benzo[*b*]thiophen-2-yl]phenylmethanone;

(3-benzyloxybenzo[*b*]thiophen-2-yl)phenylmethanone;

[3-(2,3-difluorobenzyloxy)benzo[*b*]thiophen-2-yl]phenylmethanone;

sodium 2-(4-cyanobenzoyl)benzo[b]thiophen-3-olate;

4-[3-(2-chloro-4-fluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(3,4-dichlorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(3-trifluoromethylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2-cyanobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(3-cyanobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(4-cyanobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(3,5-bis-trifluoromethylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

methyl 4-[2-(4-cyanobenzoyl)benzo[b]thiophen-3-yloxymethyl]benzoate;

4-[3-(4-fluoro-2-trifluoromethylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-(3-pentafluorophenylmethoxybenzo[*b*]thiophene-2-carbonyl)benzonitrile;

4-[3-(2,6-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(4-trifluoromethylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2-chlorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(biphenyl-2-ylmethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(4-bromo-2-fluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2-methylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2,6-dichlorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(3-chlorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2-bromobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(4-bromobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-(3-benzyloxybenzo[*b*]thiophene-2-carbonyl)benzonitrile;

4-[3-(3-bromobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2,5-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(3,4-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(3,5-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2,4-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2,3-difluorobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(4-methanesulfonylbenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(4-iodobenzyloxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-{3-[2-(4-chlorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-[3-(2-oxo-2-phenylethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-{3-[2-(2-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-[3-(2-biphenyl-4-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-[3-(2-oxo-2-*p*-tolylethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-{3-[2-(4-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-[3-(2-adamantan-1-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-{3-[2-(4-fluorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-{3-[2-(3-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-{3-[2-(2-benzyloxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-{3-[2-(4-benzyloxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-{3-[2-(3,4-dimethoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-{3-[2-(2,4-dimethoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-[3-(2-naphthalen-2-yl-2-oxoethoxy)benzo[*b*]thiophene-2-carbonyl]benzonitrile;

4-{3-[2-(4-benzyloxy-3-methoxyphenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}benzonitrile;

4-{3-[2-(2-benzyloxy-5-fluorophenyl)-2-oxoethoxy]benzo[*b*]thiophene-2-carbonyl}-benzonitrile;

(3-hydroxybenzofuran-2-yl)phenylmethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-(4-chlorophenyl)ethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-(2-methoxyphenyl)ethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-biphenyl-4-ylethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-*p*-tolylethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-(4-methoxyphenyl)ethanone;

1-adamantan-1-yl-2-(2-benzoylbenzofuran-3-yloxy)ethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-(4-fluorophenyl)ethanone;

methyl 2-(2-benzoylbenzofuran-3-yloxy)-3-methoxypropionate;

2-(2-benzoylbenzofuran-3-yloxy)-1-(2-benzyloxyphenyl)ethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-(4-benzyloxyphenyl)ethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-(3,4-dimethoxyphenyl)ethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-(2,4-dimethoxyphenyl)ethanone;

2-(2-benzoylbenzofuran-3-yloxy)-1-naphthalen-2-ylethanone;

and also the stereoisomers thereof, the racemates thereof and the pharmaceutically acceptable salts.

18. (Currently Amended) Process for the preparation of the compounds of the formula (I) according to claim 1 ~~any one of the preceding claims~~, comprising the step consisting in using the compound of the formula (IV):



(IV)

on a halo derivative (V):

$$Hal\text{-}R_1$$

~~in which, in formulae (IV) and (V), X and R1-R6 are as defined in any one of the preceding claims~~, in equimolar amount, in a polar solvent, at a temperature of between -20 and 200°C.

19. (Currently Amended) Process according to Claim 18, for which the said compound of the formula (IV) is prepared by addition of the corresponding derivative of the formula (II):



(II)

in which ~~R3-R6 and X are as defined in any one of Claims 1 to 16, and~~ R represents a hydrogen atom or an alkyl radical, to a 2-haloethanone derivative of the formula (III):



(III)

in which Hal represents a halogen atom, and ~~R2 is as defined in any one of Claims 1 to 16~~, in a polar solvent, at a temperature of from -20 to 200°C, followed by cyclization in a polar solvent at a temperature of from -20 to 200°C.

20. (Currently Amended) Process for the preparation of the compounds of the formula (I) according to Claim 18 ~~or 19~~, for which the said polar solvent is chosen from: ethanol, methanol, water, DMF, NMP, DMSO, iPrOH.

21. (Original) Pharmaceutical compositions comprising a compound of the formula (I):



in which:

X = O or S;

R1 is chosen from:

- Alk-COOH,
- Alk-C(=O)-$(O)_m$-Ar,
- Alk-C(=O)-$(O)_m$-Het,
- Alk-C(=O)-$(O)_m$-Alk,
- Alk-C(=O)-$(O)_m$-cycloalkyl,
- Alk-C(=O)NRR',
- Alk-$(O)_m$-Ar,
- Alk-O-Alk,
- Alk-O-Alk-Ar,

- Alk-O-Het,

R2 is chosen from -Alk, -Ar and -cycloalkyl;

R3, R4, R5 and R6, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, $-CF_3$, -NRR' and $-NO_2$;

in which, in the definitions of R1-R6:

each of the Alk, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -COOH, -NRR', $-C(=O)-(O)_mAlk$, -Het and $-NO_2$;

each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -AlkAr, -COOH, $-C(=O)-(O)_mAlk$, $-Alk-C(=O)-(O)_m-Alk$, -NRR', -Het, $-NO_2$, $-S(O)_nAr$ and $-S(O)_nAlk$;

R and R' are chosen independently from H and Alk;

m = 0 or 1;

and also the stereoisomers thereof, the racemates thereof and the pharmaceutically acceptable salts.

22. (Cancel)

23. (Original) Use of a compound of the formula (I):



in which:

X = O or S;

R1 is chosen from:

- Alk-COOH,

- $Alk-C(=O)-(O)_m-Ar$,

- Alk-C(=O)-$(O)_m$-Het,
- Alk-C(=O)-$(O)_m$-Alk,
- Alk-C(=O)-$(O)_m$-cycloalkyl,
- Alk-C(=O)NRR',
- Alk-$(O)_m$-Ar,
- Alk-O-Alk,
- Alk-O-Alk-Ar,
- Alk-O-Het,

R2 is chosen from -Alk, -Ar and -cycloalkyl;

R3, R4, R5 and R6, which may be identical or different, are chosen independently from H, -Hal, -OH, -Alk, -OAlk, -CN, $-CF_3$, -NRR' and $-NO_2$;
in which, in the definitions of R1-R6:
each of the Alk, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -COOH, -NRR', -C(=O)-$(O)_m$Alk, -Het and $-NO_2$;
each of the Ar, which may be identical or different, is optionally and independently substituted by one or more groups chosen from -Hal, -OAlk, -Alk, -Ar, -OAlkAr, -OH, -CN, -OAr, $-CF_3$, -AlkAr, -COOH, -C(=O)-$(O)_m$Alk, -Alk-C(=O)-$(O)_m$-Alk, -NRR', -Het, $-NO_2$, -S$(O)_n$Ar and -S$(O)_n$Alk;
R and R' are chosen independently from H and Alk;
m = 0 or 1,
and also the stereoisomers thereof, the racemates thereof and the pharmaceutically acceptable salts.

for the preparation of a medicament for reducing hyperglycaemia.

24. (Original) Use of a compound of the formula (I) according to Claim 23, for which the said medicament is for the treatment of diabetes.

25. (Currently Amended) Use of a compound of the formula (I) according to Claim 23 ~~or 24~~, for which the said medicament is for the treatment of non-insulin-dependent diabetes.

26. (Currently Amended) Use of a compound of the formula (I) according to claim 23 ~~any one of Claims 23, 24 and 25~~, for which the said medicament is for the treatment of dyslipidaemia and/or obesity.

27. (Currently Amended) Use according to claim 23 ~~any one of Claims 23 to 26~~, for which the said medicament is for the treatment of diabetes-related microvascular and macrovascular complications.

28. (Original) Use of a compound of the formula (I) according to Claim 27, for which the microvascular and macrovascular complications are chosen from atherosclerosis, arterial hypertension, inflammatory processes, macroangiopathy, microangiopathy, retinopathy and neuropathy.

29. (Cancel)